Wei et al., 2009 - Google Patents
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteinsWei et al., 2009
View PDF- Document ID
- 3719204009288110101
- Author
- Wei J
- Kitada S
- Rega M
- Stebbins J
- Zhai D
- Cellitti J
- Yuan H
- Emdadi A
- Dahl R
- Zhang Z
- Yang L
- Reed J
- Pellecchia M
- Publication year
- Publication venue
- Journal of medicinal chemistry
External Links
Snippet
Guided by nuclear magnetic resonance (NMR) binding assays and computational docking studies, a series of 5, 5′ substituted apogossypol derivatives was synthesized that resulted in potent pan-active inhibitors of antiapoptotic Bcl-2 family proteins. Compound 8r inhibits …
- 230000002401 inhibitory effect 0 title abstract description 92
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wei et al. | Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins | |
| Wei et al. | BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins | |
| Wei et al. | Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins | |
| Abulwerdi et al. | 3-Substituted-N-(4-hydroxynaphthalen-1-yl) arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation | |
| Besbes et al. | New dimension in therapeutic targeting of BCL-2 family proteins | |
| US8039668B2 (en) | Naphthalene-based inhibitors of anti-apoptotic proteins | |
| Gloaguen et al. | First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies | |
| Bajwa et al. | Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review | |
| Tang et al. | Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins | |
| Palchaudhuri et al. | The complex role of the triphenylmethyl motif in anticancer compounds | |
| Zhang et al. | 3-Thiomorpholin-8-oxo-8 H-acenaphtho [1, 2-b] pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure− activity relationship studies | |
| Chen et al. | Mcl-1 inhibitors: a patent review | |
| Mangiatordi et al. | Cannabinoid receptor subtype 2 (CB2R) in a multitarget approach: perspective of an innovative strategy in cancer and neurodegeneration | |
| Barelier et al. | Fragment-based deconstruction of Bcl-xL inhibitors | |
| US10766886B2 (en) | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof | |
| West et al. | Differential effects of procaspase-3 activating compounds in the induction of cancer cell death | |
| Wei et al. | Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins | |
| Rega et al. | SAR by interligand nuclear Overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-xL and Mcl-1 | |
| Feng et al. | Design, synthesis, and interaction study of quinazoline-2 (1 H)-thione derivatives as novel potential Bcl-xL inhibitors | |
| Koukoulitsa et al. | Biological and computational evaluation of resveratrol inhibitors against Alzheimer’s disease | |
| Kumara et al. | Design, synthesis, characterization, and antioxidant activity studies of novel thienyl-pyrazoles | |
| WO2013142281A1 (en) | Inhibition of mcl-1 and/or bfl-1/a1 | |
| Wei et al. | An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins | |
| Peery et al. | Synthesis and identification of a novel lead targeting survivin dimerization for proteasome-dependent degradation | |
| Doshi et al. | Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4 H-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis |